Out @NatureAging 🚨 We propose a cost-effective 2-step workflow to determine Aβ-status in memory clinics: 🩸 pTau217-based risk stratification (step 1; >90% accuracy) followed by confirmatory CSF/PET (step 2) only in uncertain pts (~30%). @OskarHansson9 https://t.co/YouBuikZiv

Do p-tau217 levels rise without amyloid or tau aggregates? 🐻 In our Acta Neuropathologica paper, we show that 🩸 p-tau217 increases ~300% during bear hibernation, while hibernating hamsters also show ⬆️ p-tau but no changes in MTBR tau. https://t.co/8QgRj9hfR9

Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals. Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET

Excited our recent work is now in print in @CellCellPress! Why does tau protein impair memory in Alzheimer's? We show that high-molecular-weight tau from patient brains disrupts neuronal bursts by suppressing CaV2.3 calcium channels.

🚨 In this paper in @NatureCommuniations, we find that Down syndrome #Alzheimer exhibits unique pathological features compared with sporadic late-onset and autosomal dominant AD with important implications for treatment strategies. https://t.co/5ruQ0RUThn

We developed a #CSF assay for #SV2A and found it correlates strongly with UCB-J PET in Alzheimers—more so than other established CSF synaptic markers. A promising step toward fluid biomarkers of #synaptic density #biomarkers #neurodegeneration https://t.co/VTxwnQ9O49

NPTX2 is emerging as a key neurodegeneration biomarker, but measurement tools are limited. We developed a low-volume, automated Simoa assay for its quantification in CSF #biomarkers #neurodegeneration https://t.co/tjukHVl7qd

Our most important paper, out now! A massive international collaboration, led by @AlexisMoscoso9, featuring over 6500 visually assessed tau PET scans covering the #Alzheimers spectrum! Thank you very much to the numerous contributors and collaborators who made this gem possible.

After more than 3 years of work, visualizing over 6,500 tau PET scans, and countless manuscript revisions, I still have to blink twice to believe it: our paper “Frequency and Clinical Outcomes Associated With Tau PET Positivity” is now published in JAMA. https://t.co/8iGcly62Qe

Fluid biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay @AlamarBio @andrealessa https://t.co/PZTKwEjqyW

New paper out! We explored immune-related proteins in CSF and plasma in Alzheimer's disease, linking TSPO PET to neuroinflammation. Highlights: CXCL1 and TNFRSF11B in CSF show strong links to TSPO and AD pathways. Check it out!

We're entering a new era of #Alzheimers blood testing—fully automated platforms now deliver fast, accurate #pTau217 results for use in primary & secondary care. Proud to share senior authorship and proud of this multi-centre European collaboration. 🔗

I am very honored to have my work recognized by the AAIC Neuroscience Next! Thank you to all my mentors, colleagues, and friends who have been incredibly supportive along the way. @alzassociation @goteborgsuni

🎉 Congratulations to our PhD student @giovannacollar for receiving the AAIC Neuroscience Next ‘One to Watch’ Award at #AAICNeuro 🇺🇸! A well-deserved recognition by the @alzassociation for her contributions to neuroscience research. 👏✨

Thrilled to be back home at @BarcelonaBeta as the Lead of the Neuroimaging Group! 🎉 Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇

and now the paper is out... https://t.co/8cXZYHjcoI 📣 33 different ways to measure #blood #pTau 👉Mass Spec, semi & fully-auto immunoassays 🩸#pTau217 consistently best 📈Corr. between #pTau217 assays = optimism for standardisation @jmschott @AshviniKeshavan @wagnersbrum

Whatever we may think the Big Data or mouse studies show, only well conducted and adequately powered clinical trials can tell us whether repurposed drugs can help in neurodegenerative disorders. Most likely (in my view) they will not. If only it was so easy!

Check out our plasma p-tau round robin study! Just published at @alzdemjournals

New *open access* paper in @alzdemjournals — with the @alzassociation #GBSC we compared 33 different plasma p-tau assays. TLDR — Plasma p-tau217 on several platforms was the best at discriminating Alzheimer’s from controls https://t.co/GUOb2nRbTG

🚨 New Study just out in @LancetGH 🧠 @lucasudaros, @vbwyll, @crisaguzzoli & colleagues used a machine learning model to determine the most important risk factors for cognitive and functional decline in Brazil and other Latin American Countries 🧶1👇

🚨 Open PhD Position 🚨 I am looking to hire a doctoral student for a fully funded PhD position focused on understanding the role of neuroinflammation and synaptic loss in Alzheimer’s disease and other proteinopathies with novel PET imaging biomarkers/ https://t.co/oaqyd8GZBZ